J&J’s first-quarter profit beats estimates even as Stelara sales disappoint
By Michael Erman April 14 (Reuters) – Johnson & Johnson reported first-quarter earnings that beat Wall Street expectations on Tuesday and raised its full-year forecast, as robust demand for most cancers drug Darzalex and psoriasis therapy Tremfya greater than offset a steep falloff in sales of its blockbuster autoimmune drug Stelara. The drug and gadget…